Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab biosimilar
- Development stage
- Preclinical
- Lead developer
- Celltrion
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Trastuzumab biosimilar (Japan Biotechno Pharma) is a monoclonal antibody biosimilar of the reference biologic trastuzumab, currently in development by Japan Biotechno Pharma for the treatment of HER2-positive cancers. Like the reference product, it targets the Human Epidermal Growth Factor Receptor 2 (HER2), a transmembrane protein overexpressed in certain breast and gastric cancers. The mechanism of action involves binding to the extracellular domain of HER2, which inhibits ligand-independent HER2 signaling, prevents the proteolytic cleavage of the HER2 extracellular domain, and triggers antibody-dependent cellular cytotoxicity (ADCC) against tumor cells. Japan Biotechno Pharma includes this candidate in its portfolio focused on manufacturing technology development and sales.
- Other names
- Trastuzumab biosimilar
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab biosimilar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab biosimilar.